Venatorx Pharmaceuticals’ cefepime-taniborbactam was superior to standard of care meropenem for treating complicated urinary tract infections in Phase 3 trials, the Pennsylvania-based company announced last week.
The investigational antibiotic—which targets carbapenem-resistant Enterobacterales and P. aeruginosa—generated bacterial eradication in 70% of participants compared to 58% treated with meropene, and cefepime-taniborbactam’s superiority was maintained through a late follow-up,…
Venatorx Pharmaceuticals announced Monday that it has entered into a licensing agreement with Roche to advance drug treatments for infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.
Boston University-led nonprofit CARB-X gave the Pennsylvania-based company $15 million between 2019 and 2020 to develop a new class of oral antibiotics to treat infections caused by multidrug-resistant N. gonorrhoeae.
The Global Antibiotic Research and Development Partnership (GARDP) announced two agreements to help develop antibiotics against three carbapenem-resistant (CR) pathogens that WHO has listed as critical.
First, GARDP and Venatorx Pharmaceuticals said last week that the nonprofit will provide development support for the Pennsylvania-based company’s investigational antibiotic against CR Enterobacterales and P. aeruginosa in return for exclusive rights to distribute the drug, cefepime-…
CARB-X announced this week that it is giving Pennsylvania-based VenatoRx up to $4.1 million upfront and $8.9 million more in potential milestone payments to develop a new class of oral antibiotics to treat infections caused by multidrug-resistant Neisseria gonorrhoeae.
Last year, CARB-X also awarded Summit Therapeutics up to $4.5 million to develop new antibiotic compounds against gonorrhea.
Multiple organizations announced investments in tackling antibiotic resistance over the past week.
First, the U.S. Department of Health and Human Services announced last week that its Biomedical Advanced Research and Development Authority will give up to $20.7 million over two years to Pennsylvania’s VenatoRx to share costs needed to bring to market a novel antibiotic for drug-resistant infections, with the option to extend the contract to a total cost-share of $86.8 million over six…